Prostate cancer screening: a new way forward or another false start?

Affiliations

Comment

Peter C Albertsen. Nat Rev Urol. 2021 Oct.

. 2021 Oct;18(10):579-580.

doi: 10.1038/s41585-021-00513-w.

No abstract available

Comment on

The BARCODE1 Pilot: a feasibility study of using germline single nucleotide polymorphisms to target prostate cancer screening.
Benafif S, Ni Raghallaigh H, McGrowder E, Saunders EJ, Brook MN, Saya S, Rageevakumar R, Wakerell S, James D, Chamberlain A, Taylor N, Hogben M, Benton B, D'Mello L, Myhill K, Mikropoulos C, Bowen-Perkins H, Rafi I, Ferris M, Beattie A, Kuganolipava S, Sevenoaks T, Bower J, Kumar P, Hazell S, deSouza NM, Antoniou A, Bancroft E, Kote-Jarai Z, Eeles R. Benafif S, et al. BJU Int. 2022 Mar;129(3):325-336. doi: 10.1111/bju.15535. Epub 2021 Aug 15. BJU Int. 2022. PMID: 34214236 Free PMC article.

1. Catalona, W. J. et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N. Engl. J. Med. 324, 1156–1161 (1991). - DOI
1. Lane, J. A. et al. Active monitoring, radical prostatectomy, or radiotherapy for localized prostate cancer: study design and diagnostic baseline results of the ProtecT randomized phase 3 trial. Lancet Oncol. 15, 1109–1118 (2014). - DOI
1. Nordström, T. et al. Comparison between the four-kallikrein panel and prostate health index for predicting prostate cancer. Eur. Urol. 68, 139–146 (2015). - DOI
1. Grönberg, H. et al. Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic study. Lancet Oncol. 16, 1667–1676 (2015). - DOI
1. Eklund, M. et al. MRI-targeted or standard biopsy in prostate cancer screening. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2100852 (2021). - DOI - PubMed